Empirical use of vancomycin in neonates. Risks greater than benefits

Authors

  • Víctor Garay Gutiérrez

DOI:

https://doi.org/10.61651/rped.2017v69n1p36-42

Keywords:

Vancomycin, Infant, Newborn

Abstract

Vancomycin is a frequently prescribed antimicrobial drug in neonatal intensive care units. Its empiric use has been evaluated by comparing its risks. Being the risks greater than the benefits it is important to preserve its use for resistant bacterial infection in neonates and nosocomial severe infections.

Downloads

Download data is not yet available.

Downloads

Published

2017-12-31

How to Cite

1.
Garay Gutiérrez V. Empirical use of vancomycin in neonates. Risks greater than benefits. Rev Peru Pediatr [Internet]. 2017 Dec. 31 [cited 2024 Oct. 17];69(1):36-42. Available from: https://pediatria.pe/index.php/pedperu/article/view/277

Issue

Vol. 69 Num. 1 (2017)

Section

REVIEW

Categories

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors will retain the copyright and grant the right to publish their work in the journal while allowing third parties to share it under the Creative Commons Attribution license.

Articles are published under a Creative Commons license that allows sharing and adaptation with appropriate credit. CC BY 4.0 license. Available in English at https://creativecommons.org/licenses/by/4.0/

Authors may use other information disclosure formats as long as the initial publication in the journal is cited. The dissemination of the work through the Internet is recommended to increase citations and promote academic exchanges.

The published content does not necessarily reflect the specific point of view of the journal, and the authors assume full responsibility for the content of their article.